Related Experiment Video

Updated: Feb 18, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.6K

Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian

Xin Li1, Junpeng Wang2, Yun Yao1

  • 1Department of Molecular Biology, College of Basic Medical Sciences, Norman Bethune Health Science Center, Jilin University, Changchun 130021, China.

Oncotarget
|November 16, 2017
PubMed
Abstract

Insights

Nivolumab, pembrolizumab, and ipilimumab plus sargramostim offer the best balance of benefits and safety for advanced melanoma patients. While ipilimumab plus nivolumab improves progression-free survival, it has higher toxicity.

Area of Science:

  • Oncology
  • Immunotherapy
  • Melanoma Treatment

Background:

  • Advanced melanoma presents a significant therapeutic challenge.
  • Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment.
  • Comparing the efficacy and safety of various ICI-related therapies is crucial.

Purpose of the Study:

  • To compare and rank the effectiveness of nine immune checkpoint inhibitor-related therapies for advanced melanoma.
  • To evaluate the balance between therapeutic benefits and patient acceptability for each treatment strategy.

Main Methods:

  • Systematic literature search of PubMed, Cochrane, Web of Science, and ClinicalTrials.gov for randomized controlled trials.
  • Bayesian network meta-analysis framework to compare treatment efficacy and safety.
  • Inclusion of 12 trials with 5413 patients in the analysis.

Main Results:

  • Nivolumab, pembrolizumab, and ipilimumab plus sargramostim demonstrated a favorable benefit-risk profile.
  • Ipilimumab plus nivolumab showed superior progression-free survival (PFS) but higher toxicity.
  • Nivolumab and pembrolizumab exhibited the best safety profiles with significantly fewer adverse events.

Conclusions:

  • Nivolumab, pembrolizumab, and ipilimumab plus sargramostim are potential optimal treatments for advanced melanoma.
  • The choice of therapy should consider the balance between efficacy (PFS, OS) and tolerability.
  • Ipilimumab plus nivolumab is highly effective for PFS but carries a significant toxicity burden.
Keywords:
advanced melanomaefficacyimmune checkpoint inhibitorsafetytherapy

More Related Videos

Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
787